RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Seven scientific investigators and clinicians from research institutions around the world are the first recipients of the Talents Awards initiated by Talecris Biotherapeutics, Inc. The awarded grants support investigator-initiated trials conceived by researchers and clinicians with an interest in intravenous immunoglobulin (IGIV) therapies. Talents (Talecris New Trials Support) is designed to further advance research that addresses the use of IGIV in antibody replacement as well as immune modulation therapies. Talecris produces and markets Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified), a leading IGIV therapy.
